je.st
news
CRL's bottom line continues to be driven by biotech growth, CEO says
2015-03-06 03:45:14| Biotech - Topix.net
For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday. The growth for CRL, which Foster called " an interesting phenomenon worth noting, " comes as biotech companies have become the drug discovery engines of Big Pharma.
Tags: line
bottom
says
growth
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||